Syntekabio Completes Patent Registration for 'AI-Based Drug Efficacy Substance Discovery Method'

ShinTekkaBio, an AI-based new drug development company (CEO Jeong Jong-seon), announced on the 17th that it has completed the registration of a domestic patent for a method of discovering active substances through AI-based protein-ligand 3D binding analysis.

The patent is titled "Method and device for discovering active substances through 3D binding structural information between protein and ligand." Through this patent, ShinTekkaBio has established its technological capability and commercialization foundation to rapidly and accurately discover new drug candidates in AI-based new drug development pursued by the company.

Conventional new drug development involves conducting the new drug development process (non-clinical trials/clinical trials) according to regulations using substances derived from candidate substance discovery and screening processes conducted in research institutes at the early stage of development. However, most early development stages require significant time and cost, and the success rate is generally quite low. Therefore, it is very important for new drug development companies to establish measures to improve efficiency and accuracy and reduce costs from the early stages of therapeutic development.

ShinTekkaBio expects that through this patent, it will be able to rapidly derive precise and targeted therapeutic development that surpasses existing limitations. The 3D structural information of protein-ligand was converted into text information to improve processing speed. In terms of accuracy, it implements the accuracy of the optimal binding structure at a level similar to screening by 3D structural analysis and provides an efficient screening method, enabling rapid and accurate derivation of effective substances with improved efficacy and safety, as well as the generation of various derivatives. This is expected to contribute to shortening the new drug development cycle and increasing efficiency.

Jeong Jong-seon, CEO of ShinTekkaBio, stated, "Through accuracy improvement, this will be a game changer that can dramatically transform the high-cost, low-efficiency landscape of new drug development," and added, "We plan to focus on expanding ShinTekkaBio’s AI-based new drug development platform and global commercialization by applying it to joint research and service contracts with various domestic and international new drug development companies."

This content was produced with the assistance of AI translation services.